作者更正：高程序性死亡受体配体1（PD-L1）表达与晚期胆管癌患者对帕博利珠单抗的治疗反应相关。
Author Correction: High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer.
作者信息
Ahn Soomin, Lee Jong- Chan, Shin Dong Woo, Kim Jaihwan, Hwang Jin- Hyeok
机构信息
Departments of Pathology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Republic of Korea.
Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, Republic of Korea.
出版信息
Sci Rep. 2020 Dec 3;10(1):21552. doi: 10.1038/s41598-020-78512-x.
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
摘要
本文的一个修订版本已发表，可通过本文顶部的链接获取。
相似文献
1
Author Correction: High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer.作者更正：高程序性死亡受体配体1（PD-L1）表达与晚期胆管癌患者对帕博利珠单抗的治疗反应相关。
Sci Rep. 2020 Dec 3;10(1):21552. doi: 10.1038/s41598-020-78512-x.
2
Author Correction: Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.作者更正：PD-1/PD-L1抑制剂治疗晚期非小细胞肺癌的真实世界证据及临床观察
Sci Rep. 2020 Jan 27;10(1):1525. doi: 10.1038/s41598-020-58487-5.
3
Author Correction: Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination.作者更正：乳腺癌细胞中药物诱导的PD-L1表达和细胞应激反应可通过联合用药实现平衡。
Sci Rep. 2020 Mar 5;10(1):4463. doi: 10.1038/s41598-020-60964-w.
4
Author Correction: Regulation of sister chromatid cohesion by nuclear PD-L1.作者更正：细胞核程序性死亡配体1对姐妹染色单体黏连的调控
Cell Res. 2020 Sep;30(9):823. doi: 10.1038/s41422-020-0365-y.
5
Author Correction: Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.作者更正：细胞周期蛋白D - 细胞周期蛋白依赖性激酶4通过cullin 3 - SPOP使程序性死亡蛋白1配体（PD - L1）不稳定以控制癌症免疫监视。
Nature. 2019 Jul;571(7766):E10. doi: 10.1038/s41586-019-1351-8.
6
Author Correction: PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis.作者更正：PD-L1介导的gasdermin C表达使癌细胞中的凋亡转变为焦亡，并促进肿瘤坏死。
Nat Cell Biol. 2020 Nov;22(11):1396. doi: 10.1038/s41556-020-00599-1.
7
Author Correction: NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?作者更正：英国国家卫生与临床优化研究所（NICE）拒绝批准派姆单抗用于铂类难治性尿路上皮癌：是否有更大的益处？
Nat Rev Urol. 2020 Sep;17(9):540. doi: 10.1038/s41585-020-0361-5.
8
Author Correction: Elevated numbers of PD-L1 expressing B cells are associated with the development of AIDS-NHL.作者更正：表达程序性死亡受体配体1（PD-L1）的B细胞数量增加与艾滋病相关非霍奇金淋巴瘤（AIDS-NHL）的发生有关。
Sci Rep. 2020 Jan 15;10(1):748. doi: 10.1038/s41598-020-57442-8.
9
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.帕博利珠单抗联合曲妥珠单抗治疗曲妥珠单抗耐药的晚期 HER2 阳性乳腺癌（PANACEA）：一项单臂、多中心、Ib-2 期试验。
Lancet Oncol. 2019 Mar;20(3):371-382. doi: 10.1016/S1470-2045(18)30812-X. Epub 2019 Feb 11.
10
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).雷莫芦单抗联合帕博利珠单抗治疗既往治疗的晚期或转移性胆道癌患者：非随机、开放标签、I 期试验（JVDF）。
Oncologist. 2018 Dec;23(12):1407-e136. doi: 10.1634/theoncologist.2018-0044. Epub 2018 May 31.
引用本文的文献
1
IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.IMbrave 151：一项关于阿替利珠单抗联合贝伐单抗及化疗治疗晚期胆管癌患者的随机II期试验。
Ther Adv Med Oncol. 2021 Jul 31;13:17588359211036544. doi: 10.1177/17588359211036544. eCollection 2021.
2
Actionability evaluation of biliary tract cancer by genome transcriptome analysis and Asian cancer knowledgebase.通过基因组转录组分析和亚洲癌症知识库对胆管癌进行可操作性评估。
Oncotarget. 2021 Jul 20;12(15):1540-1552. doi: 10.18632/oncotarget.28021.
Zotero 插件